Stock 0JW9 MEI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MEI Pharma, Inc. London S.E.

Equities

0JW9

US55279B3015

Market Closed - London S.E.
Other stock markets
 14:35:44 01/03/2023 GMT 		After market 17:16:50
4.336 USD -91.91% Intraday chart for MEI Pharma, Inc. 2.8 -35.42%
05-09 MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
04-11 MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
MEI Pharma, Inc. Announces Board Changes
MEI Pharma Solicits Proxies from Shareholders
Anson Funds hires Legion Partners' Gupta to build out activism strategy
MEI Pharma Issues Statement Regarding Anson Advisors and Cable Car?s Actions
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
MEI Pharma Reports Institutional Purchase of 32,040 Shares Along With 6,000 Put Options
MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab in Patients with Previously Treated Metastatic Colorectal Cancer
MEI Pharma, Inc. cancelled the acquisition of Infinity Pharmaceuticals, Inc. from The Vanguard Group, Inc. and others.
Anson Funds and Cable Car Capital Respond to MEI Pharma
MEI Pharma Responds to Anson and Cable Car Solicitation
Infinity Pharmaceuticals Shareholders Approve MEI Pharma Merger Deal
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEIP Stock
  4. 0JW9 Stock
  5. News MEI Pharma, Inc.
  6. Other languages